ABSI
Absci CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$452.94M
P/E Ratio
—
EPS
$-0.84
Beta
2.01
52W High
$5.23
52W Low
$2.18
50-Day MA
$2.77
200-Day MA
$3.09
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Absci Corp
Absci Corp (ABSI) is a pioneering biotechnology company revolutionizing drug discovery through its state-of-the-art AI-driven biology platform. Focused on the rapid generation of high-quality proteins and therapeutic candidates, Absci significantly accelerates traditional development timelines while lowering associated costs. The company is dedicated to transforming the biopharmaceutical landscape by equipping partners with innovative tools to develop and manufacture next-generation therapies with unparalleled efficiency and precision. With a robust pipeline of collaborations and proprietary initiatives, Absci is strategically positioned to drive significant advancements in disease treatment and modern drug development practices.
Fundamentals
| Revenue (TTM) | $2.80M |
| Gross Profit (TTM) | $-77.92M |
| EBITDA | $-112.98M |
| Operating Margin | -5453.00% |
| Return on Equity | -62.50% |
| Return on Assets | -36.30% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $1.25 |
| Price-to-Book | 2.48 |
| Price-to-Sales (TTM) | 161.77 |
| EV/Revenue | 118.14 |
| EV/EBITDA | -0.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -2.30% |
| Shares Outstanding | $153.02M |
| Float | $135.03M |
| % Insiders | 13.35% |
| % Institutions | 76.36% |
Analyst Ratings
Consensus ($8.03 target)
2
Strong Buy6
Buy1
HoldData last updated: 4/7/2026